Clarke Capital Partners

Biolexis Therapeutics is a biotechnology company specializing in the discovery and development of small molecule therapeutics for various medical conditions, including cancer, immune-mediated disorders, neurodegenerative diseases, and inflammatory conditions. Founded by Dr. David Bearss, a cancer biologist with expertise in small-molecule drug development, and Dr. Hariprasad Vankayalapati, a medicinal chemist skilled in lead candidate identification, the company leverages their extensive experience in wet-lab research and therapeutic development. Biolexis employs a proprietary AI-enabled discovery platform, Moleculern™, which utilizes laboratory-generated molecular data and advanced computational tools to create accurate structural models of protein targets. This innovative approach enhances the efficiency and effectiveness of drug discovery, allowing the rapid identification and development of novel clinical candidates while improving safety and efficacy profiles. Through its unique chemical-biological methodology, Biolexis aims to reduce costs and increase the probability of success in clinical trials for a wide range of therapeutic applications.

Giddy simplifies decentralized finance (DeFi) for cryptocurrency holders. Its platform offers secure private key management, fast fiat transfers, streamlined smart contract interactions, and rich data analytics. Giddy enables users to own their crypto and put it to work easily, charging modest service fees.

Brandless is an omnichannel consumer platform and online marketplace based in San Francisco. Founded in 2015, it offers a broad range of products across groceries and pantry items, home goods, beauty and personal care, health and wellness, baby care, and pet products. The company emphasizes better-for-you and better-for-all products and seeks to empower shoppers to make thoughtful, responsible choices through quality ingredients, responsible sourcing, and community-driven validation. It pursues a collaborative approach, prioritizing people over promotion and focused on creating a mission-driven marketplace that supports simpler, more intentional shopping across multiple channels.

Brandless is an omnichannel consumer platform and online marketplace based in San Francisco. Founded in 2015, it offers a broad range of products across groceries and pantry items, home goods, beauty and personal care, health and wellness, baby care, and pet products. The company emphasizes better-for-you and better-for-all products and seeks to empower shoppers to make thoughtful, responsible choices through quality ingredients, responsible sourcing, and community-driven validation. It pursues a collaborative approach, prioritizing people over promotion and focused on creating a mission-driven marketplace that supports simpler, more intentional shopping across multiple channels.

Curza Global, LLC is a therapeutics company focused on developing innovative drugs for infectious diseases and oncology. Established in 2013 and headquartered in Salt Lake City, Utah, with an additional office in Cambridge, Massachusetts, Curza specializes in creating novel therapeutics to combat antibiotic-resistant bacteria. Its lead program features a new class of broad-spectrum antibiotics targeting ESKAPE pathogens, which include several drug-resistant Gram-negative bacteria. This class of antibiotics is inspired by natural products and aims to exploit an unutilized binding site on the bacterial ribosome. Additionally, Curza is advancing a program that develops antibiofilm antibiotics designed to effectively kill bacteria in biofilm phenotypes. As resistance to existing therapies continues to rise, Curza addresses a significant unmet medical need in the field of infectious diseases.